

REMARKS

In the specification the same amendments have been made as were made in the parent of this application, namely, Application No. 09/674,973. In addition, on page 1 of the specification a paragraph has been added to identify this application as a divisional application.


Claims 1-32 have been canceled without prejudice. Claims 33-59 have been added. The independent claims now present in the application are Claims 33, 35-38, 45 and 47-51.

Applicants submit that no new matter has been added by any of these amendments.

Applicants note that all of the peptides recited in Claims 33-59 arise from a frameshift mutation in the BAX gene. Of those peptides, the Seq ID No. 1 peptide and the Seq ID No. 9 peptide are fragments of the Seq ID No. 5 peptide, and the Seq ID No. 10 peptide, the Seq ID No. 11 peptide, and the Seq ID No. 12 peptide are fragments of the Seq ID No. 7 peptide. In addition, the Seq ID No. 5 peptide and the Seq ID No. 7 peptide contain overlapping sequences. Accordingly, Applicants submit that all of the claims can be searched at once, without undue effort.

Applicants' undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 530-1010. All correspondence should be directed to our address given below.

Respectfully submitted,


John W. Behringer
Registration No. 23,086
Attorney for Applicants

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

JWB/HC

DC_MAIN 157292v1